Literature DB >> 30652097

The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers.

Haruhiko Takeda1,2, Hiroki Nishikawa2,3, Yukio Osaki2,4.   

Abstract

Entities:  

Year:  2018        PMID： 30652097      PMCID： PMC6295387          DOI： 10.21037/hbsn.2018.08.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  4 in total

1.  Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.

Authors:  Lejia Sun; Huayu Yang; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-12

2.  Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.

Authors:  Jianzhen Lin; Kun Dong; Yi Bai; Songhui Zhao; Yonghong Dong; Junping Shi; Weiwei Shi; Junyu Long; Xu Yang; Dongxu Wang; Xiaobo Yang; Lin Zhao; Ke Hu; Jie Pan; Xinting Sang; Kai Wang; Haitao Zhao
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.

Authors:  Elena De Mattia; Erika Cecchin; Michela Guardascione; Luisa Foltran; Tania Di Raimo; Francesco Angelini; Mario D'Andrea; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

4.  Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma.

Authors:  Yunxiu Luo; Xiaopeng Huang; Jiabin Zhan; Shuai Zhang
Journal:  Int J Gen Med       Date:  2021-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.